Skip to main content

BioNTech vs Moderna: Revenue, Profit and Business Model

BioNTech had ~$3.2B of annual revenue in FY2025 and a net loss of ~$1.3B. Moderna had $1.9B of annual revenue in FY2025 and a net loss of $2.8B.

Latest financial snapshot

BioNTech

Latest annual revenue
~$3.2B (FY2025)
Net income
~-$1.3B
Net margin
-39.6%
Revenue growth
+61.6% a year, FY2017–FY2025

Moderna

Latest annual revenue
$1.9B (FY2025)
Net income
-$2.8B
Net margin
-145.2%
Revenue growth
+37.8% a year, FY2016–FY2025

Financial summary

BioNTech

BioNTech went from a ~$202 million (€179.1 million) net loss in 2019 to ~$11.6 billion (€10.29 billion) of net profit on ~$21.4 billion (€18.98 billion) of revenue in 2021, almost all from Comirnaty. Revenue then fell to ~$19.6 billion (€17.31 billion) in 2022, ~$4.32 billion (€3.82 billion) in 2023 and ~$3.11 billion (€2.75 billion) in 2024, when it posted a ~$752 million (€665.3 million) net loss. FY2025 revenue rose 4.3% to ~$3.24 billion (€2.87 billion) only because BMS collaboration revenue was booked in Q3, while the net loss widened to ~$1.29 billion (€1.14 billion) on ~$2.37 billion (€2.10 billion) of R&D and legal settlement costs. In 2026 the decline resumed: H1 revenue fell to ~$253 million (€223.7 million), the H1 net loss reached ~$1.53 billion (€1.35 billion), and full-year revenue guidance was cut to €1.6-1.9 billion. The cushion is ~$18.8 billion (€16.6 billion) of cash and securities at June 30, 2026, which also funds a $1.0 billion ADS buyback launched in May 2026. BioNTech skyrocketed in value during the global pandemic, maintaining a market valuation generally exceeding $20 billion driven by its mRNA pipeline.

Moderna

Moderna went from $803 million of revenue in 2020 to $18.5 billion in 2021 and $19.3 billion in 2022, earning $12.2 billion and $8.4 billion of net income in those years. Revenue then fell to $6.8 billion in 2023, $3.2 billion in 2024 and $1.94 billion in 2025, with net losses of $4.7 billion, $3.6 billion and $2.8 billion. In 2025 Moderna cut operating expenses by about $2.2 billion (roughly 30%) and ended the year with $8.1 billion in cash and investments. Q2 2026 revenue was $145 million with a $782 million net loss; management guided to up to 10% revenue growth for 2026 and cash costs of about $4 billion. Moderna, Inc. is a major American pharmaceutical and biotechnology company pioneering messenger RNA (mRNA) therapeutics, sustaining a market valuation typically over $40 billion.

Revenue and profit by year

BioNTech

BioNTech revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025~$3.2B~-$1.3B-39.6%+4.3%Source
FY2024~$3.1B~-$751.8M-24.2%-28.0%Source
FY2023~$4.3B~$1.1B24.4%-77.9%Source
FY2022~$19.6B~$10.7B54.5%-8.8%Source
FY2021~$21.4B~$11.6B54.2%+3834.6%Source
FY2020~$545M~$17.2M3.2%+344.1%Source
FY2019~$122.7M~-$202.4M-164.9%-14.9%Source
FY2018~$144.2M~-$54.3M-37.6%+107.1%Source
FY2017~$69.6M~-$96.8M-139.1%—Source
Full BioNTech financials

Moderna

Moderna revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$1.9B-$2.8B-145.2%-39.9%Source
FY2024$3.2B-$3.6B-110.0%-52.7%Source
FY2023$6.8B-$4.7B-68.8%-64.4%Source
FY2022$19.3B$8.4B43.4%+4.3%Source
FY2021$18.5B$12.2B66.1%+2200.2%Source
FY2020$803M-$747M-93.0%+1233.7%Source
FY2019$60.2M-$514M-853.7%-55.4%Source
FY2018$135.1M-$384.7M-284.8%-34.4%Source
FY2017$205.8M-$255.9M-124.3%+89.9%Source
FY2016$108.4M-$216.2M-199.5%—Source
Full Moderna financials

Where the revenue comes from

BioNTech

  • COVID-19 vaccine (Comirnaty)

    majority of revenue

    BioNTech's 50% share of gross profit on Pfizer sales outside Germany, plus direct German sales. Lower demand drove H1 2026 revenue down to ~$253 million (€223.7 million) from ~$501 million (€443.6 million).

  • Collaboration and licensing revenue

    material, lumpy

    Mainly Bristol Myers Squibb payments for pumitamig; BioNTech expects to recognize ~$693 million (€613 million) of BMS collaboration revenue in Q3 2026.

  • Government contract and services

    small, stable

    A pandemic-preparedness contract with the German government and service businesses.

  • Future oncology product sales

    not yet generating revenue

    Depends on approvals for pumitamig, its ADCs and other late-stage candidates.

Moderna

  • Product SalesPrimary

    Commercial sales of Moderna's mRNA vaccines, led by COVID and RSV products.

  • Collaboration Revenue

    Complementary

    Revenue from development collaborations, partner programs, and shared pipeline work.

  • Grants And Other Revenue

    Complementary

    Government, nonprofit, and other support tied to vaccine and platform development.

  • Future Pipeline Commercialization

    Potential

    Revenue potential from respiratory combinations, oncology, rare disease, and other mRNA medicines if approved.

Business model and strategy

BioNTech

How it makes money

BioNTech SE operates a biotechnology commercialization and clinical development model, generating revenue through commercial vaccine sales, pharmaceutical partnership profit splits, licensing agreements, and research milestone payments. The company commercializes the BNT162b2 (Comirnaty) mRNA COVID-19 vaccine globally in collaboration with Pfizer, sharing gross profits and manufacturing responsibilities.

Growth strategy

BioNTech's stated goal is to become a multi-product oncology company by 2030. The plan rests on three groups of medicines: next-generation immunomodulators led by pumitamig, now in seven pivotal trials across lung, breast, colorectal and gastric cancer, and gotistobart; antibody-drug conjugates such as trastuzumab pamirtecan (HER2) and elfetabart drozuntecan (B7-H3), which has been given to more than 1,000 patients;

Competitive advantage

BioNTech's economic moat is grounded in its proprietary mRNA technology platform, structural immunology expertise, and specialized clinical manufacturing infrastructure.

BioNTech business model in full

Moderna

How it makes money

Moderna earns most of its revenue from net product sales of mRNA vaccines: Spikevax and mNEXSPIKE for COVID-19, mRESVIA for RSV, and from the 2026-2027 season mFLUSIVA for influenza. Buyers are governments, national immunization programs, pharmacy chains, wholesalers and health systems, so sales are concentrated in the autumn and winter vaccination season.

Growth strategy

Moderna is narrowing its pipeline to programs with near-term commercial potential: respiratory vaccines (COVID, RSV, flu and combinations), individualized cancer therapy with Merck, and a small set of rare-disease and latent-virus programs.

Competitive advantage

Moderna's advantages are a validated mRNA and lipid nanoparticle platform, a large patent estate on modified mRNA, in-house manufacturing in Norwood, Massachusetts plus onshore plants in the UK, Canada and Australia, and regulatory experience across approved respiratory products.

Moderna business model in full

Questions about BioNTech vs Moderna

Which company has higher revenue — BioNTech SE or Moderna, Inc.?

BioNTech SE had ~$3.2B (FY2025), while Moderna, Inc. had $1.9B (FY2025). By latest annual revenue, BioNTech SE is the larger business, with Moderna, Inc. showing a smaller revenue base.

What is the market cap of BioNTech SE vs Moderna, Inc.?

BioNTech SE's market capitalisation stands at $24.7B, while Moderna, Inc.'s is $72.7B. Moderna, Inc. carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to BioNTech SE.

How does revenue per employee compare for BioNTech SE and Moderna, Inc.?

BioNTech SE has $415k / employee in revenue per employee, while Moderna, Inc. has $414k / employee. Headcounts may use different dates, so the ratio alone does not establish which business operates more efficiently.

How do BioNTech SE and Moderna, Inc. make money?

BioNTech SE and Moderna, Inc. generate revenue in fundamentally different ways. BioNTech SE: BioNTech SE operates a biotechnology commercialization and clinical development model, generating revenue through commercial vaccine sales, pharmaceutical partnership profit splits, licensing agreements, and research milestone payments. Moderna, Inc.: Moderna earns most of its revenue from net product sales of mRNA vaccines: Spikevax and mNEXSPIKE for COVID-19, mRESVIA for RSV, and from the 2026-2027 season mFLUSIVA for influenza.

Which company is valued higher relative to revenue — BioNTech SE or Moderna, Inc.?

On a price-to-sales (P/S) basis, BioNTech SE trades at 7.6x P/S and Moderna, Inc. at 37.4x P/S. Moderna, Inc. commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to BioNTech SE. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.

Is BioNTech SE bigger than Moderna, Inc.?

By last reported revenue, BioNTech SE (~$3.2B (FY2025)) is the larger company compared to Moderna, Inc. ($1.9B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the BioNTech vs Moderna overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.